CSPC PHARMACEUT.GR. ADR4 (CVGU) - Net Assets
Based on the latest financial reports, CSPC PHARMACEUT.GR. ADR4 (CVGU) has net assets worth €34.86 Billion EUR (≈ $40.76 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€46.00 Billion ≈ $53.78 Billion USD) and total liabilities (€11.14 Billion ≈ $13.02 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CSPC PHARMACEUT.GR. ADR4 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €34.86 Billion |
| % of Total Assets | 75.79% |
| Annual Growth Rate | 8.07% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.81 |
CSPC PHARMACEUT.GR. ADR4 - Net Assets Trend (2021–2024)
This chart illustrates how CSPC PHARMACEUT.GR. ADR4's net assets have evolved over time, based on quarterly financial data. Also explore total assets of CSPC PHARMACEUT.GR. ADR4 for the complete picture of this company's asset base.
Annual Net Assets for CSPC PHARMACEUT.GR. ADR4 (2021–2024)
The table below shows the annual net assets of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2024. For live valuation and market cap data, see CVGU market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €33.87 Billion ≈ $39.59 Billion |
-3.29% |
| 2023-12-31 | €35.02 Billion ≈ $40.94 Billion |
+10.67% |
| 2022-12-31 | €31.64 Billion ≈ $36.99 Billion |
+17.94% |
| 2021-12-31 | €26.83 Billion ≈ $31.37 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CSPC PHARMACEUT.GR. ADR4's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 35.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €23.34 Billion | 72.35% |
| Other Components | €8.92 Billion | 27.65% |
| Total Equity | €32.26 Billion | 100.00% |
CSPC PHARMACEUT.GR. ADR4 Competitors by Market Cap
The table below lists competitors of CSPC PHARMACEUT.GR. ADR4 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WOORI FIN. GRP SP.ADR/3
F:2WGA
|
$11.06 Billion |
|
Webster Financial Corporation
NYSE:WBS
|
$11.06 Billion |
|
CPFL Energia S.A
SA:CPFE3
|
$11.06 Billion |
|
Impala Platinum Holdings Ltd
JSE:IMP
|
$11.07 Billion |
|
Industrivarden AB ser. A
ST:INDU-A
|
$11.03 Billion |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
$11.03 Billion |
|
DraftKings Inc
NASDAQ:DKNG
|
$11.03 Billion |
|
REXEL S.A. ADR EO 5
F:E7V0
|
$11.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CSPC PHARMACEUT.GR. ADR4's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 33,203,208,000 to 32,264,695,000, a change of -938,513,000 (-2.8%).
- Net income of 4,328,035,000 contributed positively to equity growth.
- Dividend payments of 3,233,815,000 reduced retained earnings.
- Share repurchases of 1,579,098,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €4.33 Billion | +13.41% |
| Dividends Paid | €3.23 Billion | -10.02% |
| Share Repurchases | €1.58 Billion | -4.89% |
| Other Changes | €56.43 Million | +0.17% |
| Total Change | €- | -2.83% |
Book Value vs Market Value Analysis
This analysis compares CSPC PHARMACEUT.GR. ADR4's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.62x to 1.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.17 | €3.52 | x |
| 2022-12-31 | €2.53 | €3.52 | x |
| 2023-12-31 | €2.80 | €3.52 | x |
| 2024-12-31 | €2.81 | €3.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CSPC PHARMACEUT.GR. ADR4 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.41%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.92%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.38x
- Recent ROE (13.41%) is below the historical average (18.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 21.57% | 20.11% | 0.80x | 1.34x | €3.01 Billion |
| 2022 | 20.17% | 19.69% | 0.74x | 1.38x | €3.07 Billion |
| 2023 | 17.69% | 18.68% | 0.68x | 1.39x | €2.55 Billion |
| 2024 | 13.41% | 14.92% | 0.65x | 1.38x | €1.10 Billion |
Industry Comparison
This section compares CSPC PHARMACEUT.GR. ADR4's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $30,306,294,667
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | €34.86 Billion | 21.57% | 0.32x | $11.04 Billion |
| Bayer AG NA (BAYN) | $36.86 Billion | 19.90% | 1.04x | $43.70 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $400.12 Million | -1.97% | 0.49x | $1.65 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $31.64 Billion | 19.25% | 0.32x | $10.18 Billion |
| Grifols S.A (G0FB) | $6.85 Billion | 9.13% | 1.27x | $1.99 Billion |
| Sanofi (SNW2) | $69.03 Billion | 9.01% | 0.74x | $105.72 Billion |
| AstraZeneca PLC (ZEGA) | $37.06 Billion | 8.87% | 1.60x | $252.57 Billion |
About CSPC PHARMACEUT.GR. ADR4
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more